Member Info for avctIPmatters

Excellent expansion well done ONDO .

gmcc

Old news : James Richard HESELTINE appointed Company Secretary 26 June 2024 .

https://find-and-update.company-information.service.gov.uk/officers/3OEItBgOU41egpof9u6vxj61w2c/appointments

tittle-tattle - dd-h : on the panel of this event : trust keeping avacta on track applying her skills & expertise .

"monday, november 4 corporate compliance for life science companies"

https://www.eventbrite.com/e/corporate-compliance-for-life-science-companies-tickets-1042393124897?mc_cid=f5462ba0ae&mc_eid=171476ea2a

---------------------------

n.e. healthcare executive networkn.e. healthcare executive network

2,002 followers2,002 followers

5d • 5 days ago

follow

as life sciences companies grow and seek funding, corporate compliance becomes a key factor in their success to meet regulatory requirements and gain the trust of investors and partners.

join us on monday, november 4th at 8 am est at foley hoag llp in boston for a discussion featuring a panel of seasoned experts from the life sciences sector as well as trusted service providers. panel attendees include candice cantelli meklis, svp of finance operations at flagship pioneering; john han****, partner and co-chair of capital markets at foley hoag llp; matt macneil, director at crosscountry consulting; darlene deptula-hicks, board member and cfo of crimson consulting; and claire jin, vice president at jpmorganchase.

register here: https://lnkd.in/gzcnw9t2 hashtag#nehen hashtag#corporatecompliance hashtag#lifesciences hashtag#lifesciencescompliance

Good Morning Great that Avacta have a basket of assets all capable in their own right to provide some form of £-$ future payments /cash into Avacta coffers .

2nd/3rd GEN pipeline very exciting . Avacta AVA6000 is the most advanced and likely to be the first candidate to be approved for clinical commercial drug patient use ..

---------------

--- pre|CISION® platform (DOX ) -- 1st GEN still has to be delivered :

"The clinical development of AVA6000 is ongoing in patients with FAP-positive disease and cancers with predicted sensitivity to the anthracycline mechanism of action. These cancer types include breast cancer, head and neck cancers (salivary gland subset) and soft tissue sarcomas.

https://tinyurl.com/2p8xmsyt

"Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer

Triple positive breast cancer (TPBC) is one of the most aggressive breast cancer. Due to the unique cell phenotype, aggressiveness, metastatic potential and lack of receptors or targets, chemotherapy is the choice of treatment for TNBC. Doxorubicin (DOX), one of the representative agents of anthracycline chemotherapy, has better efficacy in patients with metastatic TNBC (mTNBC).

Adding new manufacturer /product

https://biomolecularsystems.com/myra-liquid-handling-system/

https://www.launchdiagnostics.com/product/the-myra-liquid-handling-system/

-----------------------

Launch Diagnostics LimitedLaunch Diagnostics Limited

1,938 followers1,938 followers

4h • 4 hours ago

Launch Diagnostics Ltd is pleased to add the Myra instrument from Biomolecular Systems to our molecular diagnostics repertoire for PCR setup!

The Myra is designed to optimise PCR workflows by combining advanced motion control and precision pipetting with effortless automation.

- Precision Pipetting & Motion Control: Engineered specifically for PCR, the Myra ensures accuracy and consistency with minimal hands on time.

- Integrated Camera Calibration: Calibrate plasticware with a single click.

- Seamless Cycler Integration: Integration & runfile export to PCR cyclers eliminates manual data transfers, with associated error reduction.

- Contamination Prevention: UV LED on the pipetting head, replaceable HEPA filter, and closed waste container for secure, contamination-free setups.

- Small Footprint: Compact, multifunctional configuration maximises lab space.

Paired with Launch Diagnostics’ wide range of PCR assays, Myra allows for expansion or streamlining of PCR repertoires without requiring additional staff or large equipment.

To learn more please visit the website or speak to your local Territory Manager.

hashtag#PCR hashtag#LiquidHandling hashtag#LaboratoryAutomation hashtag#Diagnostics hashtag#Biotech

https://lnkd.in/e9d5zmAX

ONDO listed : :

https://insurtechdigital.com/top10/top-10-green-insurance-companies

"Great to see so much interest in the poster presentations of our two novel preCISION programs at #ENASymp24! #AVCT"

https://x.com/avacta/status/1849418466412863543/photo/2

For those like me understanding the science might be of interest . Avatca seem to tick all the good points .

https://www.bing.com/videos/riverview/relatedvideo?&q=75-fold+increase+in+therapeutic+index+what+does+that+mean+%3f&&mid=54DAA5A4591D261A646B54DAA5A4591D261A646B&&mcid=257EABDE43DA49AA823D690285448114&FORM=VRDGAR

The value is in the IP assets - no more needs said,

gmcc

NathanR999 Thanks for taking the time to respond . Take it you work in the industry .

You would think use of Diagnostic products that can reduce time consuming manual checking & processing would be of beneift & be in great demand for patient care . LD been around a long time have good hospital contracts in place ,as you say distribute some excellent Manufactuer products .

Coris just a minnow - Would expect offload Coris first .

Anyway now just a side show for Avacta - However no immediate panic to sell LD .

"The Avacta management team and Board continue to explore all available pathways to provide optionality for financing its clinical therapeutics programs over the longer term, including divestment of the Diagnostics Division, partnering, attracting global specialist biotechnology investors and potentially a NASDAQ dual listing, on which further updates will be provided in the coming months."

Note added Michelle Morrow, PhD Chief Scientific Officer to Leadership page today - (Tony Gardiner Chief Financial Officer still on page - replacememt expected November ) -

https://avacta.com/about/leadership/

Yes @ 2phevs & others thanks for sharing -great research . ONDO nice little stock to hold .

Just need to continue incremental units installed & add a few new partners - good business model -every new unit added improves recurring revenue stream . Ondo will soon become a profitable commercial company .

Making it a mandatory requirement on home insurance policies might be a bit of a stretch however not that daft as happens with security on doors /windows etc . Leakbot does seem to be a win /win for everyone involved ..

Take you word for that @ NathanR999 : What value would you put on LD acquisition ? Profit Gross Margins seem OK

LD sales coverage recently extended to include Germany .

"Launch Diagnostics is a licensed reseller and distributor of AIX-1000 AGGLUTINATION PROCESSOR FOR SYPHILIS RPR SEROLOGY

Launch Diagnostics, part of the Avacta group, provides pathology solutions encompassing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, Belgium, Luxemburg, France through Launch Diagnostics SAS and to the Republic of Ireland through ACCUSAY Diagnostics.

Offering a large portfolio of diagnostic kits, laboratory instrumentation and services, our product range has expanded over the years to include a comprehensive range of EIA, single test devices, serology products, molecular assays and instrumentation."

Some quite expensive per item - Gross priofit on sales approx 45% ; Other main distributors maybe interested in taking over LD share of the market ,

https://www.fishersci.com/shop/products/aix1000-agglutination-processor/23700100#:~:text=Fully%20automate%20the%20process%20of%20

"Fully automate the process of RPR syphilis testing with this agglutination processor. Gold Standard Diagnostics™ AIX1000™ Agglutination Processors can process 192 samples with full walk away capabilities. Supplier: GSD 00400 Catalog No. 23-700-100 $71,417.00 / Each of 1"

https://www.gsdx.us/aix-1000

----------------------

https://www.launchdiagnostics.com/product/aix-1000-agglutination-processor-for-syphilis-rpr-serology/

https://www.linkedin.com/company/launch-diagnostics/posts/?feedView=all

--------------------------

Launch Diagnostics LimitedLaunch Diagnostics Limited

1,938 followers1,938 followers

56m • 56 minutes ago

Gold Standard Diagnostics’ AIX 1000 distributed by Launch Diagnostics, is a fully automated RPR testing instrument for non-treponemal syphilis confirmation. It produces up to 192 screening or titration results in 90 minutes, reducing hands on time, with quicker turn-around times, in comparison to manual methods.

The onboard camera with pattern recognition and a user-friendly software ensures standardised, objective interpretation. Results are archived and all images can be accessed for reviewing & training purposes.

For further information, please visit https://lnkd.in/eD-Ta2wK

Or contact your local Territory manager

hashtag#goldstandarddiagnostics hashtag#launchdiagnostics hashtag#syphilis hashtag#RPR

Avacta get a mention ( courtesy of twitter )

"In October 2024, Avacta Group plc announced the incorporation of two new preclinical oncology assets, AVA6103 and AVA7100, into its portfolio of preicision-enabled drug conjugates."

Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight

"The antibody-drug conjugate market is on an exhilarating growth trajectory, fueled by innovative therapies and precision medicine. With advancements in targeted treatments and a surge in cancer cases, the demand for ADCs is skyrocketing. As biotech companies harness cutting-edge technology, the ADC market is poised to revolutionize cancer care and deliver hope to patients worldwide."

https://finance.yahoo.com/news/global-antibody-drug-conjugate-market-213100245.html

Avacta Diagnostics - How best to dispose of assets ?

Coris Bioconcept makes products - Launch Diagnostics distributes products - in the main operate as separate operations .

Might be easier to offload attract different buyers if sold individually or will they attract better value if kept together - My bet is they sell them separately .

(Affimers could be excluded or included in any negotiations at the moment parked with Coris )

Good Morning -

Coris partner in Vietnam promoting O.K.N.V.I. RESIST‑5 !

https://www.linkedin.com/company/coris-bioconcept/posts/?feedView=all

------------

CORIS BIOCONCEPTCORIS BIOCONCEPT

2,740 followers2,740 followers

18h • 18 hours ago

Follow

📅 Monday News!

Today, we wanted to express our gratitude 🙏 to Viet Anh Scientific 🇻🇳 for their outstanding participation as a sponsor at the International Conference on Emergency Medicine & Critical Care Medicine held on September 20-21, 2024, in Da Nang city.

Thank you for having showcased our rapid tests for carbapenemase detection 🧫, with special emphasis on the O.K.N.V.I. RESIST‑5 !

We have received really positive feedback from leading clinicians across Vietnam. This level of engagement from🔝 professionals reinforces the relevance and impact of our solutions in tackling antimicrobial resistance. Together, we continue to grow our presence and contribute to improving healthcare standards globally🌏.

👉 Swipe through the photos below to see the highlights of this successful conference!

hashtag#CorisBioConcept hashtag#VietAnhScientific hashtag#HealthcareInnovation hashtag#AntiMicrobialResistance hashtag#RapidTest hashtag#Vietnam hashtag#MedicalCongress

Happy with that concentrate on the science pipeline next few weeks/months -

Have every confidence that Avatca will deliver significant shareholder value , I would prefer Avatca to pay in shares to meet ongoing quarterly payments until such time they have banked additional funds to support the company plans & also the outstanding CLN balance to be paid in full .

Funding could come from various sources . From my point of view any share dilution & current SP movements not really a concern ,what matters most is Avatca need time to execute and get true value for their assets .

---------

Far better explained by RAH

https://x.com/RAH00084/status/1848278949232611567

Tempus monitise their services : Big players use their A1applications & data .

GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data.

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community.